Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.66 |
| ▸ | DRD2 | P14416 | 9/20 | 0.59 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23673811 | 0.99 | SIGMAR1 (0.64) | SIGMAR1DRD2ACKR3CA1CA2 | |
| SCHEMBL25374458 | 0.97 | SIGMAR1 (0.67) | SIGMAR1DRD2ACKR3CA1CA2 | |
| SCHEMBL22151422 | 0.93 | SIGMAR1 (0.62) | SIGMAR1DRD2ACKR3CA1CA2 | |
| SCHEMBL514343 | 0.93 | SIGMAR1 (0.61) | SIGMAR1DRD2ACKR3CA1CA2 | |
| SCHEMBL29132278 | 0.92 | SIGMAR1 (0.57) | SIGMAR1DRD2ACKR3KEAP1NFE2L2 | |
| SCHEMBL18751224 | 0.91 | SIGMAR1 (0.59) | SIGMAR1DRD2ACKR3MAPTKEAP1 | |
| SCHEMBL30091901 | 0.90 | SIGMAR1 (0.59) | SIGMAR1DRD2ACKR3CA1CA2 | |
| SCHEMBL23728664 | 0.89 | SIGMAR1 (0.58) | SIGMAR1DRD2ACKR3CA1CA2 | |
| SCHEMBL6220780 | 0.88 | SIGMAR1 (0.61) | SIGMAR1DRD2ACKR3MAPTKEAP1 | |
| SCHEMBL30750666 | 0.88 | SIGMAR1 (0.61) | SIGMAR1DRD2ACKR3MAPTKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1789049-A4 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1789049-A2 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023617-A2 | CYCLIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | HCN4, CACNA1B, SCN5A | SIGMAR1 963/4885DRD2 1834/4885ACKR3 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.